ESMO Events 2024

Meetings(se abre en una nueva pestaña/ventana) | ESMO(se abre en una nueva pestaña/ventana)

Welcome to our ESMO Virtual Congress site where we showcase the very best from ESMO's flagship portfolio.

ESMO Breast Cancer Congress 2024(se abre en una nueva pestaña/ventana)

Cancer patients and their needs are at the heart of what we do – we are committed to advancing research and integrating it into the clinic to ensure better care for our patients.

We aim to deliver a comprehensive overview of all the practice-changing new data and to make sure it has a clear roadmap to the clinic.

Mark your calendar and join a global community of experts and advocates presenting and discussing the latest ground-breaking developments and forging powerful new partnerships.

Below a collection of papers recently published in ESMO’s premier journals carefully selected to reflect the themes of the meeting.

Annals of Oncology

• ●

  Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer(se abre en una nueva pestaña/ventana) E. Harvey-Jones †, M. Raghunandan †, L. Robbez-Masson †, L. Magraner-Pardo, T. Alaguthurai, A. Yablonovitch, J. Yen, H. Xiao, R. Brough, J. Frankum, F. Song, J. Yeung, T. Savy, A. Gulati, J. Alexander, H. Kemp, C. Starling, A. Konde, R. Marlow, M. Cheang, P. Proszek, M. Hubank, M. Cai, J. Trendell, R. Lu, R. Liccardo, N. Ravindran, A. Llop-Guevara, O. Rodriguez, J. Balmana, N. Lukashchuk, M. Dorschner, L. Drusbosky, I. Roxanis, V. Serra, S. Haider, S.J. Pettitt, C.J. Lord, A.N.J. Tutt

• ●

  Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): Pilot study with 18F-Fluoroestradiol (18F-FES) CT/PET(se abre en una nueva pestaña/ventana)

  A. Gennari, E. Brain, A. De Censi, O. Nanni, R. Wuerstlein, A. Frassoldati, J. Cortes, V. Rossi, M. Palleschi, J.L. Alberini, F. Matteucci, A. Piccardo, G. Sacchetti, H. Ilhan, F. D’Avanzo, B. Ruffilli, S. Nardin, M. Monti, M. Puntoni, V. Fontana, L. Boni, N. Harbeck, on behalf of theET-FES Collaborative Group

ESMO Open

• ●

  The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients—a multicenter real-world analysis(se abre en una nueva pestaña/ventana) D. Dannehl, D. Jakob, F. Mergel, A. Estler, T. Engler, L. Volmer, M.-L. Frevert, S. Matovina, A. Englisch, C.M. Tegeler, A. Rohner, A. Seller, M. Hahn, K. Pfister, A. Fink, I. Popp, S. Lorenz, G. Tabatabai, I. Juhasz-Böss, W. Janni, S. Brucker, F.-A. Taran, A. Hartkopf, H. Schäffler

• ●

  Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)(se abre en una nueva pestaña/ventana) P. Meyer-Wilmes, J. Huober, M. Untch, J.-U. Blohmer, W. Janni, C. Denkert, P. Klare, T. Link, K. Rhiem, C. Bayer, M. Reinisch, V. Bjelic-Radisic, D.M. Zahm, C. Hanusch, C. Solbach, G. Heinrich, A.D. Hartkopf, A. Schneeweiss, P. Fasching, N. Filmann, V. Nekljudova, J. Holtschmidt, E. Stickeler, S. Loibl

ESMO Real World Data and Digital Oncology

• ●

  ESMO Guidance for Reporting Oncology real-World evidence (GROW)(se abre en una nueva pestaña/ventana) L. Castelo-Branco, A. Pellat †, D. Martins-Branco †, A. Valachis †, J.W.G. Derksen †, K.P.M. Suijkerbuijk, U. Dafni, T. Dellaporta, A. Vogel, A. Prelaj, R.H.H. Groenwold, H. Martins, R. Stahel, J. Bliss, J. Kather, N. Ribelles, F. Perrone, P.S. Hall, R. Dienstmann, C.M. Booth, G. Pentheroudakis ‡, S. Delaloge ‡, M. Koopman ‡

• ●

  Impact of artificial intelligence in transforming the doctor–cancer patient relationship(se abre en una nueva pestaña/ventana) P.-E. Heudel †, H. Crochet †, J.-Y. Blay †

ESMO affiliated journals

• ●

  Platinum chemotherapy for early triple-negative breast cancer(se abre en una nueva pestaña/ventana) Sofia RE. Mason, Melina L. Willson, Sam J. Egger, Jane Beith, Rachel F. Dear, Annabel Goodwin

• ●

  Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study(se abre en una nueva pestaña/ventana) Gilles Freyer, Noelia Martinez-Jañez, Bożena Kukielka-Budny, Malgorzata Ulanska, Hugues Bourgeois, Montserrat Muñoz, Serafin Morales, Juan Bayo Calero, Laura Cortesi, Tamás Pintér, Markéta Palácová, Nelli Cherciu, Edgar Petru, Johannes Ettl, Cécilia de Almeida, Gustavo Villanova 1, Romain Raymond 1, Christine Ta Thanh Minh, Ana Rodrigues, Marina E. Cazzaniga

• ●

  Cancer genetic counselling for hereditary breast cancer in the era of precision oncology(se abre en una nueva pestaña/ventana) M. Pensabene 1, A. Calabrese 1, C. von Arx, R. Caputo, M. De Laurentiis

• ●

  Challenges to genetic testing for germline mutations associated with breast cancer among African Americans(se abre en una nueva pestaña/ventana) S. Kamaraju, M. Conroy, A. Harris, M. Georgen, H. Min, M. Powell, R. Kurzrock

ESMO's Journal Portfolio

While diverse in nature and in content, these journals offer ESMO members and the oncology community a highly visible platform to publish important scientific studies, and a highly credible source for educational updates. Elsevier is the proud publisher of Annals of Oncology, Immuno-Oncology and Technology (IOTECH), ESMO Open, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology, and ESMO Affiliated Journals The Breast, Lung Cancer, Cancer Treatment Reviews and Clinical Lymphoma Myeloma and Leukemia.